LON:OBI

Ondine Biomedical Share Forecast, Price & News

GBX 43.50

0.00 (0.00%)

(As of 07/4/2022 12:00 AM ET)

Add

Compare

Today's Range: 42.06
▼
43.50
50-Day Range: N/A
52-Week Range: 41
▼
60

Volume: 1,748 shs
Average Volume: 52,743 shs
Market Capitalization: £84.64 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Ondine Biomedical MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

0.22 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Ondine Biomedical.

0.0 Short Interest

Short Interest
There is no current short interest data available for OBI.

0.0 Dividend Strength

Dividend Yield
Ondine Biomedical does not currently pay a dividend.
Dividend Growth
Ondine Biomedical does not have a long track record of dividend growth.

0.0 Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OBI.

1.1 News and Social Media Coverage

News Sentiment
Ondine Biomedical has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.79 average news sentiment score of Medical companies.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ondine Biomedical insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Ondine Biomedical is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ondine Biomedical is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ondine Biomedical has a P/B Ratio of 2.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

30 days | 90 days | 365 days | Advanced Chart

Receive OBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ondine Biomedical and its competitors with MarketBeat's FREE daily newsletter.

About Ondine Biomedical

Ondine Biomedical Inc., a Life sciences company, engages in the research, development, and commercialization of antimicrobial photodisinfection therapies in Canada and internationally. Its product platform is Photodisinfection, a topical light-based antimicrobial technology that eliminates harmful pathogens. The company's lead product is Steriwave, a photodisinfection based medical device that eliminates harmful nasal pathogens, which leads to healthcare-associated infections. Its product pipeline also includes development of a topical antiviral therapy for the upper respiratory tract that reduces SARS-CoV-2 titre and transmission; a solution for treatment of chronic rhinosinusitis; OND1002, a solution for disinfection of endotracheal tubes to reduce the incidence of ventilator-associated pneumonia; and OND1003, a solution for decolonization of burns and wounds. The company was incorporated in 1996 and is headquartered in Vancouver, Canada.

OBI Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Industry, Sector and Symbol

Stock Exchange: LON
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: LON:OBI
CUSIP: N/A
CIK: N/A
Web: www.ondinebio.com
Phone: 604-669-0555
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.54
Quick Ratio: 7.81

Sales & Book Value

Annual Sales: £2.57 million
Price / Sales: 32.95
Cash Flow: GBX 0.41 per share
Price / Cash Flow: 105.00
Book Value: GBX 15.20 per share
Price / Book: 2.86

Miscellaneous

Outstanding Shares: 194,585,000
Free Float: N/A
Market Cap: £84.64 million
Optionable: Not Optionable
Beta: N/A

Ondine Biomedical Frequently Asked Questions

How has Ondine Biomedical's stock performed in 2022?: Ondine Biomedical's stock was trading at GBX 42 on January 1st, 2022. Since then, OBI shares have increased by 3.6% and is now trading at GBX 43.50.
View the best growth stocks for 2022 here.
Who are Ondine Biomedical's key executives?: Ondine Biomedical's management team includes the following people:
Ms. Carolyn M. Cross C.F.A., CFA, M.B.A., MBA, Founder, CEO & Director
Dr. Nicolas G. Loebel Ph.D., Pres, CTO & Director
Mr. Thomas Dawson, Sr. VP of Corp. Devel.
Mr. Vipul Shah, VP & CFO
Mr. Mike Long, VP of Operations
Who are some of Ondine Biomedical's key competitors?: Some companies that are related to Ondine Biomedical include ProMetic Life Sciences (PLI), Horizon Discovery Group plc (HZD.L) (HZD), Precigen (PGEN), Theratechnologies (TH), VIVO Cannabis (ABCN), Emblem (EMC), Inventiva (IVA), Verona Pharma plc (VRP.L) (VRP), Redx Pharma (REDX), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), BriaCell Therapeutics (BCT), Agronomics (ANIC), Arix Bioscience (ARIX) and Circassia Group (CIR).
View all of OBI's competitors.

What is Ondine Biomedical's stock symbol?: Ondine Biomedical trades on the London Stock Exchange (LON) under the ticker symbol "OBI."
How do I buy shares of Ondine Biomedical?: Shares of OBI and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.
What is Ondine Biomedical's stock price today?: One share of OBI stock can currently be purchased for approximately GBX 43.50.
How much money does Ondine Biomedical make?: Ondine Biomedical (LON:OBI) has a market capitalization of £84.64 million and generates £2.57 million in revenue each year.
How can I contact Ondine Biomedical?: The official website for Ondine Biomedical is www.ondinebio.com. The company can be reached via phone at 604-669-0555.

This page (LON:OBI) was last updated on 7/4/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

MarketBeat Resources